Drug
JS007
JS007 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(25%)
Phase Distribution
Ph phase_3
1
25%
Ph phase_2
1
25%
Ph phase_1
2
50%
Phase Distribution
2
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Other(1)
Detailed Status
Not yet recruiting2
Recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
Trials by Status
recruiting125%
unknown125%
not_yet_recruiting250%
Recent Activity
1 active trials
Showing 4 of 4
not_yet_recruitingphase_3
JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
NCT07823348
recruitingphase_2
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
NCT06954467
not_yet_recruitingphase_1
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
NCT06370754
unknownphase_1
Clinical Study of JS007 in Patients With Advanced Solid Tumors
NCT05049265
Clinical Trials (4)
Showing 4 of 4 trials
NCT07823348Phase 3
JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
NCT06954467Phase 2
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
NCT06370754Phase 1
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
NCT05049265Phase 1
Clinical Study of JS007 in Patients With Advanced Solid Tumors
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4